These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 6361675)

  • 1. [Effects and mechanism of action of antiestrogens in breast cancer].
    Borgna JL; Rochefort H
    Pathol Biol (Paris); 1983 Nov; 31(9):775-81. PubMed ID: 6361675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects and mechanism of action of antiestrogens in breast cancer].
    Borgna JL; Rochefort H
    Sem Hop; 1984 Mar; 60(10):703-9. PubMed ID: 6322320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The elucidation of the antiestrogen and antitumoral mechanisms of tamoxifen].
    Borgna JL
    Bull Cancer; 1994 Jan; 81(1):29-37. PubMed ID: 7949581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
    Robertson JF
    Cancer Treat Rev; 2004 Dec; 30(8):695-706. PubMed ID: 15541579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pure oestrogen antagonists for the treatment of advanced breast cancer.
    Howell A
    Endocr Relat Cancer; 2006 Sep; 13(3):689-706. PubMed ID: 16954425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are breast tumours resistant to tamoxifen also resistant to pure antioestrogens?
    Wakeling AE
    J Steroid Biochem Mol Biol; 1993 Dec; 47(1-6):107-14. PubMed ID: 8274423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New vs old fashioned oestradiol antagonists in mammary carcinoma: 'in vitro' and 'in vivo' pharmacological approaches.
    de Cupis A; Schettini G; Favoni RE
    Pharmacol Res; 1999 May; 39(5):335-44. PubMed ID: 10328990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells.
    Miller MA; Lippman ME; Katzenellenbogen BS
    Cancer Res; 1984 Nov; 44(11):5038-45. PubMed ID: 6488162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of tamoxifen resistance.
    Ring A; Dowsett M
    Endocr Relat Cancer; 2004 Dec; 11(4):643-58. PubMed ID: 15613444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ICI 182,780 (Fulvestrant)--the first oestrogen receptor down-regulator--current clinical data.
    Robertson JF
    Br J Cancer; 2001 Nov; 85 Suppl 2(Suppl 2):11-4. PubMed ID: 11900210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guide-lines in the design of new antiestrogens and cytotoxic-linked estrogens for the treatment of breast cancer.
    Leclercq G; Devleeschouwer N; Heuson JC
    J Steroid Biochem; 1983 Jul; 19(1A):75-85. PubMed ID: 6887875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional activation of the oxytocin promoter by oestrogens uses a novel non-classical mechanism of oestrogen receptor action.
    Koohi MK; Ivell R; Walther N
    J Neuroendocrinol; 2005 Apr; 17(4):197-207. PubMed ID: 15842231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer.
    Nicholson RI; Hutcheson IR; Hiscox SE; Knowlden JM; Giles M; Barrow D; Gee JM
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S29-36. PubMed ID: 16113097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture.
    Osborne CK; Boldt DH; Estrada P
    Cancer Res; 1984 Apr; 44(4):1433-9. PubMed ID: 6704960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of oestradiol and tamoxifen on oestrogen receptors-alpha and -beta protein degradation and non-genomic signalling pathways in uterine and breast carcinoma cells.
    Horner-Glister E; Maleki-Dizaji M; Guerin CJ; Johnson SM; Styles J; White IN
    J Mol Endocrinol; 2005 Dec; 35(3):421-32. PubMed ID: 16326830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture.
    Lerner LJ; Jordan VC
    Cancer Res; 1990 Jul; 50(14):4177-89. PubMed ID: 2194650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
    Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
    Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antiestrogens: mechanism of action and clinical applications].
    Barrón-González A; Arias-Martínez J; Castro-Romero I
    Salud Publica Mex; 2001; 43(6):577-84. PubMed ID: 11816234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-oestrogen resistant human breast cancer cell lines are more sensitive towards treatment with the vitamin D analogue EB1089 than parent MCF-7 cells.
    Larsen SS; Heiberg I; Lykkesfeldt AE
    Br J Cancer; 2001 Mar; 84(5):686-90. PubMed ID: 11237391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antiestrogens].
    Saez S
    Presse Med; 1984 May; 13(20):1261-5. PubMed ID: 6232584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.